Prevalence and Clinical Consequences of Multiple Pathogenic Variants in Dilated Cardiomyopathy. (27th March 2023)

• Record Type: Journal Article
• Authors: Stroeks, Sophie L.V.M.; Lunde, Ida G.; Hellebrekers, Debby M.E.I.; Claes, Godelieve R.F.; Wakimoto, Hiroko; Gorham, Joshua; Krapels, Ingrid P.C.; Vanhoutte, Els K.; van den Wijngaard, Arthur; Henkens, Michiel T.H.M.; Raafs, Anne G.; Sikking, Maurits A.; Broers, Jos L.V.; Nabben, Miranda; Jones, Elizabeth A.V.; Heymans, Stephane R.B.; Brunner, Han G.; Verdonschot, Job A.J.
• Is Part Of: Circulation. Volume 16:Number 2(2023)
• Page Start: e003788
• Publication Date: 2023-03-27
• Subjects: cardiomyopathy -- dilated -- genotype -- phenotype; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Genetics -- Periodicals; Cardiovascular Diseases -- genetics; Precision Medicine; Periodical; Fulltext; Internet Resources; Periodicals; Electronic journals; Periodicals; 616.1042
• DOI: 10.1161/CIRCGEN.122.003788
• Languages: English
• ISSNs: 2574-8300

Abstract

Abstract : Background: Dilated cardiomyopathy (DCM) was considered a monogenetic disease that can be caused by over 60 genes. Evidence suggests that the combination of multiple pathogenic variants leads to greater disease severity and earlier onset. So far, not much is known about the prevalence and disease course of multiple pathogenic variants in patients with DCM. To gain insight into these knowledge gaps, we (1) systematically collected clinical information from a well-characterized DCM cohort and (2) created a mouse model. Methods: Complete cardiac phenotyping and genotyping was performed in 685 patients with consecutive DCM. Compound heterozygous digenic (LMNA [lamin]/titin deletion A-band) with monogenic (LMNA/wild-type) and wild-type/wild-type mice were created and phenotypically followed over time. Results: One hundred thirty-one likely pathogenic/pathogenic (LP/P) variants in robust DCM-associated genes were found in 685 patients with DCM (19.1%) genotyped for the robust genes. Three of the 131 patients had a second LP/P variant (2.3%). These 3 patients had a comparable disease onset, disease severity, and clinical course to patients with DCM with one LP/P. The LMNA/Titin deletion A-band mice had no functional differences compared with the LMNA/wild-type mice after 40 weeks of follow-up, although RNA-sequencing suggests increased cardiac stress and sarcomere insufficiency in the LMNA/Titin deletion A-band mice. Conclusions: In this study population, 2.3% of patients with DCM with one LP/P also have a second LP/P in a different gene. Although the second LP/P does not seem to influence the disease course of DCM in patients and mice, the finding of a second LP/P can be of importance to their relatives.